BRAINTREE, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today that it has filed a new legal action to stop Fenwal Inc.'s continued patent infringement resulting from Fenwal’s just released red cell collection kits, using a modified separation chamber. Fenwal allegedly modified its separation chamber to circumvent Haemonetics’ patent and the injunction entered by the Court prohibiting Fenwal’s continued sale of infringing products after December 1, 2010. According to statements made by Fenwal’s counsel today in the United States District Court, Fenwal is determined to proceed with commercialization without 510(k) clearance from the U.S. Food & Drug Administration.
Haemonetics filed a new lawsuit against Fenwal on account of the modified collection kit, requesting another jury trial that seeks multiple damages for willful infringement, and a permanent injunction. The new matter has been assigned to the same federal judge who issued the permanent injunction on Fenwal’s original red cell kit.
Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com .
Haemonetics Corporation
